Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avastin Advisory Committee To Assess Validity Of Objective Response Rate Endpoint

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA questions whether imaging improvements in patients with glioblastoma metaforme are sufficient to denote clinical change.
Advertisement

Related Content

Avastin Clinical Benefit Trumps Anti-Tumor Effect In Glioblastoma, ODAC Says
Avastin Clinical Benefit Trumps Anti-Tumor Effect In Glioblastoma, ODAC Says
Avastin sBLA Clears Advisory Committee, Faces Quality of Life Hurdle
Avastin sBLA Clears Advisory Committee, Faces Quality of Life Hurdle
Genentech Reports Positive Progression-Free Survival Results For Avastin In Brain Cancer Trial
Progression-Free Survival Is Meaningful Endpoint For Glioma Trials
Progression-Free Survival Is Meaningful Endpoint For Glioma Trials

Topics

Advertisement
UsernamePublicRestriction

Register

PS069204

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel